Introduction {#S0001}
============

Meningioma is the most common intracranial tumor developed from the arachnoid cells of the meninges. Although meningioma can affect both genders, its incidence is much higher among females than males. The majority of meningiomas are benign, and histologically, they can be classified into various subtypes, such as meningothelial, ﬁbrous, psammomatous, microcystic, and secretory meningiomas. Atypical and malignant meningiomas are rare (\~5%) and have a slight male dominance.[@CIT0001]

Various genetic abnormalities have been associated with the development of meningiomas.[@CIT0002] Historically, loss of chromosome 22 and focal chromosomal deletion in 1p, 6q, 14q, and 18q were first observed. Later, deletion and inactivation of *neuroﬁbromin 2* (*NF2*) gene, a tumor suppressor gene on chromosome 22q12, has been identified as the most common genetic event in patients with both sporadic meningiomas and neuroﬁbromatosis type 2.[@CIT0003] The advent of the next-generation sequencing (NGS) technology further revealed important genetic aberrations in the development of meningiomas not associated with neurofibromatosis type 2 (NF2) abnormality,[@CIT0004]--[@CIT0009] such as *TNF receptor-associated factor 7* (*TRAF7), Krupplelike factor 4* (*KLF4), v-akt murine thymoma viral oncogene homolog 1* (*AKT1), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha* (*PIK3CA), smoothened, frizzled family receptor* (*SMO*) and *SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1* (*SMARCB1*).

It is common for patients with NF2 to develop multiple meningiomas (MMs). However, the incidence of sporadic MMs in patients without a history of NF2 is low.[@CIT0010] It is much less common to find these sporadic MMs bearing different histological features in the same patient.[@CIT0011] The etiology of MM is still being debated because of two hypotheses for the development of MMs, ie, monoclonal or independent.[@CIT0012] The monoclonal hypothesis suggests that MMs originate from a certain neoplastic transformed clone that subsequently spreads along the meninges to form multi-foci.[@CIT0013],[@CIT0014] This hypothesis is supported by the observations that most sporadic MMs presented the same histological features.[@CIT0015] However, it is also possible for MMs that evolve independently and are driven by different key genetic events, such as the cases of MMs showing different histological types or grades.[@CIT0012] Nevertheless, most of the studies on the etiology of MM were performed based on histological and cytogenetic evidence. To our knowledge, the authors reported here the first comprehensive genomic profiling with whole exome sequencing (WES) on two meningiomas of different histological types in the same patient. Our results revealed distinctive somatic mutation burdens in the two tumors and supported the independent clonal origins hypotheses for the current case.

Methods {#S0002}
=======

Patient recruitment {#S0002-S2001}
-------------------

A 52-year-old male presented with headaches for 2 months was recruited from Second Affiliated Hospital of Wenzhou Medical University. Physical and neurological examinations were performed to confirm whether the patient has pathological signs. Surgery was performed in one stage for resection of both tumors which then were sent for pathological examinations. The patient received detailed information on the study and provided his written informed consent prior to inclusion in the study and has given written informed consent for the publication of information about his case. The present study complied with the Declaration of Helsinki and the experimental protocols and informed consents were approved by the Hospital Institutional Ethics Committee.

DNA extraction and whole-exome sequencing {#S0002-S2002}
-----------------------------------------

DNA from the two meningioma tissues and the corresponding patient's peripheral lymphocytes (control) were isolated by standard methods, as described before.[@CIT0016] The quality of isolated genomic DNA was verified by using 1% agarose gel electrophoresis and Qubit® DNA Assay Kit in Qubit® 2.0 Fluorometer (Life Technologies, CA, USA).

For the WES protocol, libraries were prepared for each sample with an Agilent SureSelect Human All Exon kit (Agilent Technologies, Santa Clara, CA, USA) following manufacturer's recommendations and index codes were added to each sample. A total amount of 0.6 μg genomic DNA per sample was used as input material for the DNA sample preparation. Libraries products were purified using AMPure XP system (Beckman Coulter, Beverly, MA, USA) and quantified using the Agilent high sensitivity DNA assay on the Agilent Bioanalyzer 2100 system. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using Hiseq PE Cluster Kit (Illumina) according to the manufacturer's instructions. After cluster generation, the DNA libraries were sequenced on Illumina Hiseq platform and 150 bp paired-end reads were generated.

Variant calling and bioinformatics analysis {#S0002-S2003}
-------------------------------------------

FASTQ ﬁles of exomes obtained from the three samples (one from peripheral blood and two different tumors from the same patient) were first examined by QC steps to generate high-quality clean data. Valid sequencing data were then mapped to the reference human genome (UCSC hg19) by Burrows-Wheeler Aligner (BWA) software[@CIT0017] to get the original mapping results stored in BAM format. Then, SAMtools,[@CIT0018] Picard (<http://broadinstitute.github.io/picard/>), and GATK[@CIT0019] were used to sort BAM files and do duplicate marking, local realignment, and base quality recalibration to generate final BAM file for computation of the sequence coverage and depth. Samtools (Wysoker A, *et al* 2009) mpileup and bcftools were used to do the variant calling and identify single nucleotide polymorphism, insertion and deletion (InDels). The somatic single nucleotide variants (SNVs) were detected by muTect,[@CIT0020] and the somatic InDel by Strelka.[@CIT0021] Control-FREEC (Boeva V *et al* 2012) was used to detect somatic copy number variation (CNV).

Sanger sequencing validation {#S0002-S2004}
----------------------------

The primers used for *CDH11* amplification were as follows: Forward, 5'‑CACAGCCATGCCTTTGCC‑3' and reverse, 5'‑GCCTTACCCTGCCCACAA‑3'. The primers used for *KLF4* amplification were as follows: Forward, 5'‑CACCCCACCTTCTTCACCC‑3' and reverse, 5'‑CTGGGAAGTCAAGGAGGCAC‑3'. The primers used for *TRAF7* amplification were as follows: Forward, 5'‑CATCTGCCCTGTTCCTACCTTCG‑3' and reverse, 5'‑GGCCTTACGTGGATGAGGTTCTC‑3'. PCR was conducted with 40 cycles of denaturation (95°C for 25 s), annealing (56°C for 25 s) and extension (72°C for 40 s). PCR was performed in a LineGene 9600 Plus thermal cycler (BIOER, Hangzhou Bioer Technology Co. Ltd., China), using deoxynucleotides (Takara Bio, Inc., Japan) and Tris-borate ethylenediaminetetraacetic acid (Takara Bio, Inc.) as a buffer. Amplified DNA fragments were recovered from a low melting temperature agarose gel, purified with a Magnetic Beads Genomic DNA Extraction Kit (MSi100-DNA, Enriching Biotechnology Ltd, China) and subjected to direct sequencing analysis using an automated ABI-3730 Sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Results {#S0003}
=======

Clinical characteristics of the patient {#S0003-S2001}
---------------------------------------

A 52-year-old male has presented with headaches for 2 months. Physical and neurological examination revealed normal sensation and muscle strength, normal reflexes and negative pathological signs. There was no evidence of neurofibromatosis either. Preoperative magnetic resonance imaging (MRI) scan showed a right frontal tumor with strong homogenous contrast enhancement, marked perifocal edema, and significant midline shift ([Figure1A-C](#F0001){ref-type="fig"}). Another well-demarcated and homogenously enhancing tumor was also found at the right parietal convexity, but with minimal perifocal edema ([Figure1E-G](#F0001){ref-type="fig"}). Surgery was performed in one stage and both tumors were successfully totally resected and sent for pathological examinations. The postoperative course was uneventful, and his symptoms improved after surgery. He was discharged in one week postoperatively and follow-up MRI scan 8 months later confirmed the complete removal of both tumors ([Figure 1D, H](#F0001){ref-type="fig"}).Figure 1Magnetic resonance imaging (MRI) images of the two sporadic multiple meningiomas in a 52-year-old male patient. (**A-C**) Preoperative MRI showed a right frontal tumor with strong homogenous contrast enhancement, marked perifocal edema, and significant midline shift. (**E-G**) Preoperative MRI showed another well-demarcated and homogenously enhancing tumor at the right parietal convexity, but with minimal perifocal edema. (**D, H**) Follow-up MRI scan performed 8 months later confirmed the complete removal of both tumors.

Histopathological examination {#S0003-S2002}
-----------------------------

Histopathological examination of right frontal meningioma revealed the tumor cells were in a form of syncytium-like appearance, with unclear boundaries between the cells. The nucleus was oval with fine chromatin and some of the nucleus was transparent in the middle. Cells were arranged in large lobulated structures or formed a small swirling structure. Some tumor cells were partially epithelial-differentiated and the intraepithelial microgland contained eosinophilic substances ([Figure 2A](#F0002){ref-type="fig"}). Immunohistochemistry (IHC) showed CK (+), Vimentin (+++), EMA (sporadic +), CEA (+), S-100 (−), Ki-67 (\~1%), CD34 (−), ER (−) and PR (+). Histopathological examination of the right parietal meningioma showed spindle-shaped tumor cells, parallel or bundled in a cross-shaped arrangement. There was formation of swirling structure in focal areas, with calcification scattered in a small amount of mature adipose tissues. The shapes of nucleus were long spindle, fatty spindle, or oval, with fine chromatin and some nucleus were transparent ([Figure 2B](#F0002){ref-type="fig"}). IHC showed Vimentin (+++), Ki-67 (\~1%), CK (−), and EMA (+). The right frontal meningioma was pathologically diagnosed as secretory meningioma (WHO grade I) whereas the right parietal one was fibrous meningioma (WHO grade I).Figure 2Histopathological examinations of the two sporadic multiple meningiomas. **(A**) The right frontal tumor cells showed syncytium-like appearance with unclear boundaries. Cells were arranged in large lobulated structures. Some cells were partially epithelial-differentiated and the intraepithelial microgland contained eosinophilic substances. Pathological diagnosis was secretory meningioma (WHO grade I). (**B**) The right parietal tumor showed spindle cells with bland nuclei arranged in storiform pattern, with calcification in some adipose tissues. Pathological diagnosis was fibrous meningioma (WHO grade I).

Genetic analysis of the two meningiomas {#S0003-S2003}
---------------------------------------

Given the different subtypes in both meningiomas, we tried to examine the genetic differences and the clonal relationship between two sporadic meningiomas. We applied WES on the two meningiomas to investigate all variants annotated with in-house pipeline. Somatic mutation analysis revealed, in the secretory subtype, there was a total of 1,343 SNVs (59 in the CoDing Sequence (CDS)) and 57 InDels (3 in the CDS) in a total of 1,085 genes ([Figure 3A](#F0003){ref-type="fig"}). Whereas 1034 SNVs (28 in the CDS) and 32 InDels (3 in the CDS) in a total of 798 genes were identified in the fibrous subtype (see [Tables S1](#ST0001) and [S2](#ST0002)). In addition, we found that there were 128 common genes with somatic mutations between two subtypes, whereas there were only 37 common somatic mutations (SNVs and InDels) in these common genes ([Figure 3A](#F0003){ref-type="fig"}). Focusing on the exons, there were no common genes with somatic mutations in exons of the whole genome between two subtypes ([Figure 3B](#F0003){ref-type="fig"}). Furthermore, we also performed CNV analysis that revealed only 13 gain counts in the secretory subtype, while there were 109 gain counts and 10 loss counts, including copy number loss of *NF2* and *SMARCB1*, in the fibrous subtype (see [Table S3](#ST0003)).Figure 3Distinctive somatic mutation patterns for single nucleotide variants (SNVs) and InDels in the two sporadic multiple meningiomas. (**A**) The number of genes with somatic mutations including SNVs and InDels between two subtypes. The box showed the number of SNVs and InDels in the common genes between the two subtypes. (**B**) All the genes with somatic mutations in exons of the whole genome of the two subtypes.

The two tumors also demonstrated different mutation profiles in terms of predisposing gene mutation and known driver gene mutation. For predisposing gene mutation analysis, the secretory subtype had the highest mutation burden. Besides, as compared with the control, it contained missense mutations in *TRAF7, KLF4, and CDH11*, in-frame deletion in *ELN*, a nonsense mutation in *PDE4DIP*, as well as mutations in the splice sites of *NUP214, KDM6A*, and *ZMYM2*. In contrast, the fibrous subtype had a missense mutation in *PDE4DIP*, in-frame deletion in *ZRSR2*, frame-shift deletion in *NF2*, and splice site mutation of *ZMYM2* ([Figure 4A](#F0004){ref-type="fig"}). Known driver gene mutation analysis indicated the missense mutations of *ABCB1, AHNAK, CDH11, TRAF7* and *H3F3A*, and frame-shift deletion of *KMT2D* in the secretory subtype. Whereas the fibrous subtype had missense mutations of *GMPS* and frame-shift deletion of *NF2* ([Figure 4B](#F0004){ref-type="fig"}). Significantly mutated genes analysis showed missense mutations of *LOC729159* in the secretory subtype and *RPGRIP1L* and *DPP6* in the fibrous subtype ([Figure 4C](#F0004){ref-type="fig"}). A whole-genome view of the two samples confirmed a higher number of SNV and InDel events in secretory subtype while a more prominent CNV abnormality in the fibrous subtype ([Figure 5](#F0005){ref-type="fig"}). Subsequent validation by Sanger sequencing confirmed nonsynonymous mutations in *KLF4* (c.1225A\>C, *p*.K409Q), *CDH11*(c.169T\>G, *p*.W57G) and *TRAF7* (c.1678G\>A, *p*.G560S) in secretory subtype ([Figure 6](#F0006){ref-type="fig"}).Figure 4Whole exome sequencing revealed distinctive mutational patterns in the two sporadic multiple meningiomas of different histological features. (**A**) Predisposing gene mutation analysis showed the secretory subtype had the highest mutation burden and contained missense mutations in *TRAF7, KLF4*, and *CDH11*. In contrast, the fibrous subtype had a frame-shift deletion in *NF2*. (**B**) Known driver gene mutation analysis indicated the missense mutations of *CDH11, TRAF7*, and *H3F3A* in the secretory subtype. Whereas the fibrous subtype had a frame-shift deletion of *NF2*. (**C)** Significantly mutated genes analysis showed missense mutations of *LOC729159* in the secretory subtype and *RPGRIP1L* and *DPP6* in the fibrous subtype.Figure 5The somatic mutation landscapes of the two histologically different multiple meningiomas presented in Circos plots. Chromosome ideograms are shown around the outer ring and are oriented pter--qter in a clockwise direction with centromeres indicated in red. Other tracks contain somatic alterations (from outside to inside): sequencing coverage; green dots represent the density of validated somatic insertions and deletions (InDel) and single nucleotide variants (SNV); somatic copy number variation (CNV) events are represented as loss (blue dots), gain (red dots) or normal (green dots). (**A**) Secretory subtype featured with a higher number of SNV and InDel events. (**B**) Fibrous subtype had a more prominent CNV abnormality.Figure 6Sanger sequencing validation of point mutations in the secretory subtype meningioma. (**A**) Sanger sequencing confirmed a c.1225A\>C mutation was observed in the *KLF4* gene, resulting in *p*.K409Q. (**B**) Sanger sequencing confirmed a c.169T\>G mutation was observed in the *CDH11* gene, resulting in *p*.W57G. (**C**) Sanger sequencing confirmed a c.1678G\>A mutation was observed in the *TRAF7* gene, resulting in *p*.G560S.

Discussion {#S0004}
==========

The definition of MM is generally accepted as two or more than two spatially separated meningiomas that have developed from at least two distinct brain regions. Although MMs can occur in patients with predisposing conditions such as NF2, hereditary SWI/SNF complex deficiency syndromes,[@CIT0022] Cowden syndrome,[@CIT0023] Turner syndrome[@CIT0024] and Rubinstein-Taybi syndrome,[@CIT0025] sporadic MMs with no family history are not commonly reported in the literature. Besides, most of these sporadic MMs are of the same histological subtypes[@CIT0013],[@CIT0014],[@CIT0026]--[@CIT0028] and sporadic MMs bearing different histological features or grades in the same patient are much less common. Huang et al[@CIT0015] evaluated 456 patients with an intracranial meningioma and found 8.6% of them had more than one meningioma. Compared with solitary meningiomas, MMs have their own clinical features such as female preponderance and stronger PR expression. Koh et al[@CIT0012] reported a case of MMs with both malignant and benign histological features and proposed MMs originated from multicentric neoplastic foci. Similarly, Liu et al[@CIT0011] showed the coexistence of fibrous meningioma (WHO grade I) and atypical meningioma (WHO grade II) in the same patient. More recently, Tsermoulas et al[@CIT0029] reviewed a total of 133 consecutive patients with MMs for over 25 years and 18 patients had surgical removal of more than one meningioma. Among these patients, 4 had tumors of different grades and 6 patients had meningiomas of different histological types.

Despite the lack of knowledge on the incidence of meningiomas of different histological subtypes in the same patient, there is a keen interest in revealing the etiology of MMs. Since the majority of surgically removed MMs showed the same histopathological features, it is likely they might derive from one single clone that disseminates through the subarachnoid space during the long history of this benign condition. Another hypothesis, which is supported by the observations of MMs presenting different pathological features, is that tumors can develop independently at multiple foci through different neoplastic transition mechanisms. Previous investigations have mainly focused on the molecular mechanisms underpinning the pathogenesis of solitary meningiomas by different techniques including cytogenetic analysis, gene expression arrays and NGS, and revealed a wealth of information on genetic abnormalities,[@CIT0003],[@CIT0030] the most notable of which is the *NF2* gene. However, not much is yet known about the genetic basis of those solitary MMs. Shen et al[@CIT0031] applied comparative genomic hybridization arrays and showed a distinct pattern between MMs from patients with familial predisposition and those sporadic cases. Dewan et al[@CIT0032] performed in-depth genomic profiling of two cranial meningiomas (WHO grade I and grade II) with WES and spectral karyotyping from a patient predisposed with NF2. They found, in addition to second *NF2* copy inactivation, both tumors had a low somatic burden. However, the grade II tumor exhibited a high level of genomic instability and mutations of *ADAMTSL3* and *CAPN5*, which might explain its more aggressive biological behaviors. Recently, Torres-Martı´n et al[@CIT0033] performed WES on four meningioma samples from a patient with sporadic MM. They identified three common mutational events (*NF2, FAM109B*, and *TPRXL*) for all tumors as well as unique mutations for each individual tumor. Therefore, they proposed a monoclonal origin for their particular case. That patient underwent multiple surgeries for progressive tumor growth, including a dorsal meningioma (1975), an olfactory sulcus meningioma (1987) and multiple neoplastic nodules from the frontoparietal convexity and falx (1990), over a period of 15 years. Although all tumors were diagnosed histologically as transitional meningioma, the authors did not specify which four tumor tissues, among the multiple samples they had collected, had been sequenced.

To the best of our knowledge, our current study is the ﬁrst to adopt WES on the genetic profiling of two histologically different primary sporadic MMs in the same patient. Our results showed distinctive genetic features underlying them and thus we support an independent clonal origin in the current case. For example, secretory subtype featured with a higher frequency of SNV and InDel events while the fibrous subtype had a more prominent CNV abnormality. Our results also identified some key mutations that have been associated with the development of meningiomas. Specifically, mutations in *TRAF7, KLF4*, and *CDH11* for the secretory subtype and deletion of *NF2*, copy number loss of *NF2* and *SMARCB1* for the fibrous subtype. There are several comprehensive review articles on the germline and somatic mutations underlying the pathogenesis meningiomas[@CIT0001],[@CIT0034],[@CIT0035] and a detailed analysis of those known gene mutations and their complex pathway interactions are beyond the scope of the current paper. However, we would discuss here briefly on important mutant genes that have been confirmed by Sanger sequencing. For example, we identified a c.1225A\>C (*p*.K409Q) in *KLF4*, which is consistent with previous reports.[@CIT0036]--[@CIT0038] *KLF4* belongs to a family of DNA-binding transcriptional regulators and were suggested to be involved in some cancers as potential tumor suppressor, despite the fact that *KLF4* K409Q mutation being speciﬁc for meningioma.[@CIT0039],[@CIT0040] In contrast, the *TRAF7* c.1678G\>A (*p*.G560S) mutation in our secretory subtype is relatively novel compared with previous reports (N520S, G536S, K615E, R641C and R641H).[@CIT0030] TRAF7 depletion by RNA interference has been shown to result in resistance to TNFα cytotoxicity and *TRAF7* downregulation was observed in breast cancer expression and was proposed to contribute to p53 accumulation.[@CIT0041],[@CIT0042] Nevertheless, similar to *KLF4, TRAF7* mutation is highly speciﬁc for meningioma. This concomitant *TRAF7/KLF4* mutation pattern was seen in about 8% of meningiomas and provided both diagnostic (secretory subtype) and prognostic value (better prognosis compared with NF2 type).[@CIT0030] Besides, there might be potential benefits by targeting either *KLF4, TRAF7* or both, though further research is needed.

Moreover, these authors suggest the establishment of a classification system on meningiomas by combing clinical feature, histology, and genetic mutation to better refine personalized treatments. Yuzawa et al[@CIT0030] classified meningiomas into seven genotypes: NF2, TRAF7/KLF4, TRAF7/AKT1, SMO, "Others," "Complex," and "None". They also found these genotypes were related to clinical features such as tumor location, and histological types and grades. Interestingly, both the fibrous subtype and the secretory subtype in our case matched the proposed NF2 genotype and TRAF7/KLF4 genotype. Another recent study further proposed a classification and grading system for meningioma based on DNA methylation pattern.[@CIT0043] They have shown the six methylation classes are better at predicting recurrence and prognosis than the WHO classification system. Specifically, the methylation class (MC) ben-1 is featured by NF2 mutation, 22q deletion with predominant histology of fibroblastic, transitional and atypical. While the MC ben-2 is featured by *TRAF7, KLF4, SMO*, and *AKT* mutations, balanced chromosome and secretory, transitional and meningothelial histology. Accordingly, the two meningiomas of our current case matched the MC ben-1 and MC ben-2 subclass. Therefore, our sequencing results support these molecular classification systems. In 2016 WHO classiﬁcation of the tumors of the central nervous system,[@CIT0044] molecular classiﬁcation has already been applied in the diagnosis of gliomas, as their genetic makeup can significantly influence patients' prognosis and choice of treatments. Therefore, it is also promising to incorporate molecular classiﬁcation of meningiomas into existent WHO histological classification system.

Conclusion {#S0005}
==========

Genetic profiling with NGS is a valuable supplement to conventional pathological diagnosis in answering the questions regarding the clonal origin of MMs. Further study is needed to ascertain whether these genetic abnormalities are tumorigenic or simply passenger mutations, as well as their clinical implications. Current efforts on genetic profiling of meningiomas, together with further investigation on the associations between genetic abnormalities, histology, and patients' prognosis, will help to establish a more integrate diagnosis on meningiomas including MMs.
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Table S1The number of somatic single nucleotide variant (SNV) in different tumor samplesEvent/SampleFibrousSecretoryCoDing Sequence (CDS)2859synonymous_SNP1425missense_SNP1333stopgain11stoploss00unknown00intronic659896UTR33335UTR51115splicing03ncRNA_exonic69ncRNA_intronic5256ncRNA_UTR300ncRNA_UTR500ncRNA_splicing00upstream1816downstream616intergenic217238Total10341343 Table S2The number of somatic insertion and deletion (InDel) in different tumor samplesEvent/SampleFibrousSecretoryCoDing Sequence (CDS)33frameshift_deletion31frameshift_insertion00nonframeshift_deletion01nonframeshift_insertion01stopgain00stoploss00unknown00intronic2433UTR3010UTR501splicing00ncRNA_exonic14ncRNA_intronic13ncRNA_UTR300ncRNA_UTR500ncRNA_splicing00upstream10downstream00intergenic23Total3257 Table S3The number of somatic copy number variation (CNV) in different tumor samplesSample/EventGain countGain sizeLoss countLoss sizeTotal countTotal size**Fibrous**109556,776,6391024,310,010119581,086,649**Secretory**131,725,22300131,725,223
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